Prediction of Mortality After Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction
The CADILLAC Risk Score
Amir Halkin, MD*,
Mandeep Singh, MD ,
Eugenia Nikolsky, MD*,
Cindy L. Grines, MD, FACC ,
James E. Tcheng, MD, FACC ,
Eulogio Garcia, MD||,
David A. Cox, MD, FACC¶,
Mark Turco, MD, FACC#,
Thomas D. Stuckey, MD, FACC**,
Yingo Na, MSc*,
Alexandra J. Lansky, MD, FACC*,
Bernard J. Gersh, MB, ChB, DPhil, FACC ,
William W. ONeill, MD, FACC ,
Roxana Mehran, MD, FACC* and
Gregg W. Stone, MD, FACC*,*
* Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York
Mayo Clinic and Foundation, Rochester, Minnesota
William Beaumont Hospital, Royal Oak, Michigan
Duke Clinical Research Institute, Durham, North Carolina
|| Hospital Gregorio Maranon, Madrid, Spain
¶ Mid Carolina Cardiology, Charlotte, North Carolina
# Washington Adventist Hospital, Tacoma Park, Maryland
** Moses Cone Hospital, Greensboro, North Carolina

View larger version (25K):
[in a new window]
|
Figure 1 Integer scoring system and corresponding one-year mortality rates. LVEF = left ventricular ejection fraction; TIMI = Thrombolysis In Myocardial Infarction.
|
|

View larger version (27K):
[in a new window]
|
Figure 2 Score-based risk classification system with corresponding 1-year (A) and 30-day (B) mortality rates and discriminatory performance in the CADILLAC (solid bars) and Stent-PAMI (open bars) trial datasets.
|
|

View larger version (14K):
[in a new window]
|
Figure 3 Freedom from all-cause mortality among the CADILLAC trial patients stratified by risk class.
|
|
|